Biosimilar and Biologics Market Is Expected to Reach USD 1,060.7 Billion by 2034 And Grow at a Compound Annual Growth Rate of 7.6 % | FMI Inc.
The pharmaceutical industry has made significant strides in biosimilars and biologics, offering opportunities for innovation, growth, and enhanced patient access to vital therapies.
NEWARK, Del, Aug. 27, 2024 (GLOBE NEWSWIRE) — As per the latest analysis, the is projected to be appraised at US$ 2,241.8 million by 2034, up from US$ 1500 million in 2024, advancing at a CAGR of 4.10% from 2024 to 2034.
The global biological and chemical indicators market is set to value at US$ 490.3 million in 2023. With an estimated growth rate of 5.9% CAGR during the forecast period, the market is likely to surpass US$ 866.9 million by 2033.
The global sales of bioimpedance devices market is estimated to be worth USD 650.5 million in 2024 and anticipated to reach a value of USD 1,244.2 million by 2034.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: [email protected]
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
